Opinion

Video

The Relationship Between Prostate Cancer and Cardiovascular Disease

Author(s):

Lawrence Karsh, MD, FACS,Stephen J. Freedland, MD

Experts on prostate cancer discuss the relationship between prostate cancer and cardiovascular disease, highlighting ongoing research for safer treatment.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
      Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
      Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
      Dr Louise Kostos answers a question during a Zoom video interview
      Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
      Dr Louise Kostos answers a question during a Zoom video interview
      An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
      Rana McKay, MD, on the role of radium-223 in the modern era
      Rana McKay, MD, on the role of radium-223 in the modern era
      Dr Louise Kostos answers a question during a Zoom video interview
      Dr Louise Kostos discusses PSA kinetics in mHSPC
      Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
      The importance of PSADT in high-risk, biochemically recurrent prostate cancer
      Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
      Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
      Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
      Expert discusses triplet regimens in metastatic hormone-sensitive prostate cancer
      Related Content
      Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: @ Dr_Microbe - stock.adobe.com
      April 3rd 2025

      CD46-targeting ADC shows encouraging clinical activity in mCPRC

      Hannah Clarke
      The company plans to initiate the phase 2 monotherapy trial by mid-year.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      FDA updates in urology: March 2025
      April 1st 2025

      FDA updates in urology: March 2025

      Hannah Clarke
      A recap of the FDA submissions and regulatory decisions in urology from March 2025.
      Dr. Schwen on focal therapies for prostate cancer
      January 11th 2024

      Dr. Schwen on focal therapies for prostate cancer

      Cleveland Clinic
      Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
      NeuroSAFE procedure for RARP leads to improved erectile function
      March 27th 2025

      NeuroSAFE procedure for RARP leads to improved erectile function

      Hannah Clarke
      “Our results show that by using NeuroSAFE, nearly twice as many men don’t have to face potentially life-changing loss of erectile function after prostate surgery,” says Professor Greg L. Shaw.
      Data reinforce isodose MHFRT as standard of care radiotherapy regimen
      March 22nd 2025

      Data reinforce isodose MHFRT as standard of care radiotherapy regimen

      Hannah Clarke
      “These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD.
      © 2025 MJH Life Sciences

      All rights reserved.